Trovagene, Inc. TROV Cash Flow

Trovagene, inc. (TROV)

CashFlow / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14
Operating activities
Net Income (Loss) Attributable to Parent
-4,088	-4,242	-4,141	-4,125	-3,904	-4,158	-3,769	-3,746	-4,786	-2,569	-4,291	-8,045	-9,999	-8,547	-10,191	-10,202	-10,262	-7,380	-2,735	-10,180	-7,174	-4,683	-5,375	-1,077	-3,189
Adjustments to reconcile net loss to net cash used in operating activities:
Impairment loss
-	-	-	-	-	-	-	-	-	104	0	0	485	0	0	0	0	-	-	-	-	-	-	-	-
Net gain on disposal of fixed assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-8	0	3	-	-19	0	44
Depreciation and amortization
119	364	43	-39	126	157	218	231	252	290	311	314	330	376	203	332	156	128	97	84	68	65	58	57	53
Stock-based compensation expense
177	269	266	148	200	268	278	221	1,406	895	1,421	775	920	1,561	1,829	1,301	2,811	1,187	923	1,123	711	685	405	419	559
Accretion of final fee premium
-	-	-	-	-	-	-	-	-	0	0	168	125	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of discount on debt
-	-	-	-	-	-	-	-	-	0	0	45	68	68	53	-40	93	93	59	68	124	-	-	-	-
Amortization of discount on debt
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	27	28	2	28	28	-	-	-	-
Amortization of premiums on short-term investments
-	-	-	-	-	-	-	-	-	0	0	1	-10	-45	-34	-27	0	-	-	-	-	-	-	-	-
Deferred rent
-	-	-	-	-	-325	102	84	79	-66	70	70	66	-	-	-	-	-	-	-	-	-	-	-	-
Deferred rent
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-66	0	-	-	-	-	-	-	-	-
Interest income accrued on short-term investments
-	-	-	-	-	-	-	-	-	0	0	241	-151	94	-85	75	0	-	-	-	-	-	-	-	-
Unrealized Gain (Loss) on Derivatives
2	0	13	23	-9	38	-2	711	-129	1,388	1,528	-71	555	1,787	88	52	533	378	4,017	-3,175	-1,946	205	-1,029	2,217	32
Release of clinical trial funding commitment
293	194	198	240	70	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Changes in operating assets and liabilities:
Other assets
-1	-13	35	48	-15	-146	-29	199	0	-	-	-	-	792	0	0	-2	27	-15	26	0	-	-	-	-
Accounts receivable and unbilled receivable
-97	51	29	6	-52	39	4	9	-72	-101	20	77	-20	15	-73	96	-36	-189	188	40	2	-5	2	-69	50
Prepaid expenses
-55	162	-113	15	-179	295	-125	-93	-97	226	225	-132	-110	120	68	37	51	393	-112	90	48	21	52	33	109
Operating lease right-of-use assets
-79	164	-157	-236	-73	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accounts payable and accrued expenses
88	617	450	383	3	-168	-255	587	50	-1,032	-2,189	641	-360	-332	1,008	409	1,072	-254	588	411	-383	95	384	138	14
Operating lease liabilities
-206	-200	-196	-192	-186	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other liabilities
10	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in operating activities
-3,374	-	-	-	-3,360	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Decrease in other liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-268	-	-	-	0	-	-	-	-
Net cash used in operating activities
-	-	-	-	-	-	-	-3,250	-2,856	-3,331	-6,594	-4,597	-8,758	-9,004	-7,041	-8,077	-6,915	-6,808	-5,132	-5,444	-4,732	-3,866	-3,408	-2,653	-2,798
Investing activities:
Capital expenditures
0	0	62	0	5	0	0	0	5	-35	115	9	11	25	126	318	352	984	569	440	247	127	101	15	118
Maturities of short-term investments
-	-	-	-	-	-	-	-	-	0	0	2,431	14,000	13,750	0	0	0	-	-	-	-	-	-	-	-
Purchases of short-term investments
-	-	-	-	-	-	-	-	-	0	0	0	8,804	13,308	-3,500	27,951	0	-	-	-	-	-	-	-	-
Net cash used in investing activities
0	-	-	-	-5	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in investing activities
-	-	-	-	-	-	-	-31	-5	36	-115	18,857	5,183	415	3,373	-28,270	-352	-976	-569	-440	-247	-64	-101	-15	-118
Financing activities:
Proceeds from sales of common stock and warrants
1,000	4,417	1,500	2,900	0	-	-	-	-	-	-	-	-	-	-	-	-	0	37,399	2,370	21,445	-	-	-	-
Costs related to the clinical trial funding commitment
0	0	0	0	-40	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net borrowings under debt agreements
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	515	14,471	-48
Proceeds from exercise of warrants
1,456	8	-8	17	3,282	0	0	163	1,449	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from exercise of options
-	-	-	-	-	-	-	-	-	-	-	-	-	0	134	98	133	42	254	328	236	-	-	-	-
Borrowings under equipment line of credit
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	241	550	1,086	0	0	0	-	-	-	-
Repayments under equipment line of credit
-	-	-	-	-	0	0	1,043	156	156	156	156	156	52	0	0	0	-	-	-	-	-	-	-	-
Net cash provided by financing activities
2,456	-	-	-	3,242	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net change in cash and cash equivalents
-918	-	-	-	-123	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Repayments of long-term debt
-	-	-	-	-	-	-	-	-	-	-	-	-	0	6,576	1,400	919	0	0	0	0	-	-	-	-
Net cash provided by financing activities
-	-	-	-	-	-	-	15,110	1,292	4,069	6,371	-16,662	-156	-60	3,657	-1,059	-235	1,128	38,557	3,183	21,681	61	0	14,471	-48
Effect of exchange rate changes on cash and cash equivalents
-	-	-	-	-	-	-	-	-	16	-11	3	-0	-4	0	-2	-0	0	0	0	0	-	-	-	-
Net change in cash and cash equivalents
-	-	-	-	-	-	-	11,828	-1,568	791	-349	-2,399	-3,731	-8,654	-9	-37,410	-7,503	-6,656	32,856	-2,701	16,701	-3,869	-3,510	11,802	-2,965
Supplementary disclosure of cash flow activity:
Cash paid for taxes
0	0	0	0	0	0	0	0	0	-	-	-	-	-	-	-	-	16	0	0	0	0	0	0	2
Cash paid for interest
-	-	-	-	-	-	-	6	16	18	20	329	300	297	269	260	276	266	265	265	265	176	176	65	6
Supplemental disclosure of non-cash investing and financing activities:
Preferred stock dividend payable on Series A Convertible Preferred Stock
6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	1	9
Deemed Dividend Related To Beneficial Conversion Feature Of Preferred Stock
0	-	-	-	268	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Common stock, preferred stock and warrants issued in connection with clinical trial funding commitment
0	0	0	0	1,675	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of debt costs and final payment
-	-	-	-	-	-	-	-	-	0	0	45	68	-	-	-	-	-	-	-	-	-	-	-	-
Leasehold improvements paid for by lessor
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	1,860	0	0	0	0	-	-	-	-